| 25A304 |
Jazz Pharmaceuticals, Inc. v. Robert F. Kennedy, Secretary of Health and Human Services, et al. |
District of Columbia |
2025-09-16 |
Presumed Complete |
|
administrative-law chevron-deference fda-regulation market-exclusivity orphan-drug-act statutory-interpretation |
Whether Congress implicitly ratified an FDA regulatory interpretation of the Orphan Drug Act's market exclusivity provision when it amended the statut… |
| 24-1187 |
Vanda Pharmaceuticals, Inc. v. Food and Drug Administration, et al. |
District of Columbia |
2025-05-21 |
Denied |
Response RequestedResponse WaivedRelisted (2) |
administrative-law agency-discretion drug-approval fda-regulation medical-innovation statutory-interpretation |
Whether FDA has acted contrary to its statutory mandate by substituting an evaluation of a drug development program's potential for assessing a new dr… |
| 24-1189 |
California Stem Cell Treatment Center, Inc., a California Corporation, et al. v. United States |
Ninth Circuit |
2025-05-21 |
Denied |
Amici (3)Response WaivedRelisted (2) |
drug-classification enforcement-action fda-regulation medical-law stem-cells surgical-procedure |
Whether stem cells used in surgical procedures are 'drugs' subject to FDA regulation under the FDCA and whether the FDA had a lawful basis for its enf… |
| 24-977 |
Merck Sharp & Dohme Corporation v. Doris Albrecht, et al. |
Third Circuit |
2025-03-12 |
Denied |
Amici (4) |
administrative-law drug-preemption fda-regulation pharmaceutical-liability state-law-liability warning-label |
Whether a pharmaceutical manufacturer can be held liable under state law for failure to warn when the FDA formally denies a proposed warning label cha… |
| 24A724 |
Johnny Copper, LLC v. Food and Drug Administration, et al. |
Eleventh Circuit |
2025-01-23 |
Presumed Complete |
|
administrative-law agency-overreach fda-regulation procedural-due-process regulatory-burden statutory-interpretation |
Whether the FDA exceeded its statutory authority in issuing a regulatory order that imposes substantial burdens on a regulated entity without providin… |
| 23-1125 |
Logic Technology Development LLC v. Food and Drug Administration |
Third Circuit |
2024-04-17 |
Denied |
Relisted (3) |
administrative-law agency-action arbitrary-and-capricious electronic-nicotine-delivery-system electronic-nicotine-delivery-systems fda-regulation menthol-flavoring premarket-tobacco-application premarket-tobacco-product-application retroactive-rulemaking retroactive-standard |
Whether the FDA's creation of a new, heightened standard for evaluating already-pending PMTAs for certain ENDS products was arbitrary and capricious |
| 23-1038 |
Food and Drug Administration v. Wages and White Lion Investments, L.L.C., dba Triton Distribution, et al. |
Fifth Circuit |
2024-03-19 |
Judgment Issued |
Amici (17)Relisted (2) |
administrative-law agency-decision agency-deference arbitrary-and-capricious e-cigarettes fda-regulation interstate-commerce public-health tobacco-control tobacco-regulation |
Whether the court of appeals erred in setting aside FDA's denial orders as arbitrary and capricious |
| 23A779 |
Logic Technology Development LLC v. Food and Drug Administration |
Third Circuit |
2024-02-26 |
Presumed Complete |
|
administrative-law agency-rulemaking arbitrary-capricious electronic-nicotine fda-regulation marketing-application |
Whether the FDA improperly adopted a new and heightened evidentiary burden for marketing applications for electronic nicotine delivery systems (ENDS) … |
| 23-799 |
Magellan Technology, Inc. v. Food and Drug Administration |
Second Circuit |
2024-01-24 |
Denied |
Amici (1)Relisted (4) |
administrative-procedure-act agency-rulemaking arbitrary-and-capricious circuit-split comparative-efficacy electronic-nicotine-delivery-systems ends-products fda-regulation marketing-authorization reliance-interests youth-access |
Whether FDA's denial of Petitioner's marketing applications for flavored ENDS was arbitrary and capricious |
| 23A421 |
Magellan Technology, Inc. v. Food and Drug Administration |
Second Circuit |
2023-11-15 |
Presumed Complete |
|
administrative-law arbitrary-and-capricious circuit-split evidentiary-standards fair-notice fda-regulation |
Whether the FDA's marketing denial order for electronic nicotine delivery system (ENDS) products was arbitrary and capricious by changing evidentiary … |
| 22-1112 |
Avail Vapor, LLC, et al. v. Food and Drug Administration |
Fourth Circuit |
2023-05-15 |
Denied |
Amici (3)Relisted (2) |
administrative-law administrative-procedure-act arbitrary-and-capricious evidence-standard evidentiary-standard fda fda-regulation marketing-authorization premarket-applications tobacco-product-regulation tobacco-products |
Whether FDA's marketing denial order was arbitrary and capricious |
| 21-1342 |
Jacobus Pharmaceutical Company, Inc. v. Catalyst Pharmaceuticals, Inc., et al. |
Eleventh Circuit |
2022-04-11 |
Dismissed |
|
administrative-law circuit-split drug-exclusivity fda fda-regulation lambert-eaton-myasthenic-syndrome orphan-drug-act rare-disease statutory-interpretation |
Does the Orphan Drug Act unambiguously foreclose FDA's interpretation that the scope of orphan-drug exclusivity is tied to a drug's approved use? |
| 20-1069 |
Janssen Pharmaceuticals, Inc., et al. v. A. Y., et al. |
Pennsylvania |
2021-02-05 |
Denied |
Amici (4) |
civil-liability drug-labeling fda-regulation federal-preemption impossibility-preemption off-label-use preemption state-tort-law |
Whether federal law preempts state-law claims that a manufacturer failed to provide adequate warnings relating to the off-label use of their products,… |
| 20-451 |
Jane Doe, Individually and as Parent and Guardian of Baby Doe, et al. v. Merck & Co., Inc., et al. |
Second Circuit |
2020-10-08 |
Denied |
Response Waived |
citizens-action civil-rights due-process fda-licensing fda-regulation primary-jurisdiction standing thimerosal vaccine-act vaccine-injury vaccine-mandate |
Whether courts should extend the precedent of Jacobson v. Massachusetts to require that a mandated vaccine be necessary, harm-avoidant, proportional a… |
| 23A712 |
Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al. |
Fifth Circuit |
|
Presumed Complete |
|
administrative-law chemical-abortion drug-safety fda-regulation medical-procedure reproductive-rights |
Whether the FDA's regulatory framework for chemical abortion drugs satisfies the requirements of the Food, Drug, and Cosmetic Act and does not pose un… |